Marc-Olivier Bitker
Overview
Explore the profile of Marc-Olivier Bitker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dardenne E, Manach Q, Grande P, Campi R, Gomez F, Granger B, et al.
Can J Urol
. 2019 Dec;
26(6):10039-10044.
PMID: 31860421
Introduction: To investigate the mid-term results of penile prosthesis (PP) implantation in patients with erectile dysfunction (ED) from a "real-life" historic cohort in a French academic center. Materials And Methods:...
2.
Champy C, Campi R, Grande P, De La Taille A, Mejean A, Granger B, et al.
Minerva Urol Nefrol
. 2019 Oct;
72(2):200-206.
PMID: 31619031
Background: Patients with TSC - related renal angiomyolipoma (AML) are eligible for targeted therapy with mTOR inhibitors, avoiding the morbidity of interventional management. Despite clinical criteria for TSC diagnosis have...
3.
Flippot R, Mouawad R, Spano J, Roupret M, Comperat E, Bitker M, et al.
Sci Rep
. 2017 Aug;
7(1):8540.
PMID: 28819235
Prediction of recurrence is a challenge for the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC). In these tumors, expression of long non-coding RNAs (lncRNAs) are deregulated and...
4.
Su X, Zhang J, Mouawad R, Comperat E, Roupret M, Allanic F, et al.
Cancer Res
. 2017 Jul;
77(18):4835-4845.
PMID: 28754676
Extensive dysregulation of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through next-generation sequencing. However, a scientific understanding of the cross-talk between epigenetic and genomic aberrations...
5.
Furudoi A, Varinot J, Phe V, Roupret M, Bitker M, Comperat E
Virchows Arch
. 2017 Mar;
470(5):561-565.
PMID: 28280928
Few histological data are known about patients with a first diagnosis of bladder cancer (BC) at the age ≥80 years. We describe the largest series in this patient group and...
6.
Phe V, Leon P, Granger B, Denys P, Bitker M, Mozer P, et al.
Neurourol Urodyn
. 2016 Apr;
36(3):764-769.
PMID: 27080729
Aims: To report the long-term functional outcomes of artificial urinary sphincter (AUS) implantation in female adult neurological patients suffering from stress urinary incontinence (SUI) due to sphincter deficiency. Methods: Female...
7.
Varinot J, Furudoi A, Drouin S, Phe V, Renard Penna R, Roupret M, et al.
Virchows Arch
. 2016 Mar;
468(5):619-22.
PMID: 26931741
The HOXB13 gene is a member of the homeobox gene family, and prostate development depends on HOXB13 function. HOXB13 is a very sensitive and specific marker of prostate tissue and...
8.
Phe V, Cattarino S, Parra J, Bitker M, Ambrogi V, Vaessen C, et al.
Int J Med Robot
. 2016 Mar;
13(2).
PMID: 26928974
Background: The utility of the virtual-reality robotic simulator in training programmes has not been clearly evaluated. Our aim was to evaluate the impact of a virtual-reality robotic simulator-training programme on...
9.
Renard Penna R, Cancel-Tassin G, Comperat E, Mozer P, Leon P, Varinot J, et al.
World J Urol
. 2016 Feb;
34(10):1389-95.
PMID: 26902878
Purpose: To evaluate the use of multiparametric MRI (mp MRI) parameters in order to predict prostate cancer aggressiveness as defined by pathological Gleason score or molecular markers in a cohort...
10.
Renard-Penna R, Cancel-Tassin G, Comperat E, Varinot J, Leon P, Roupret M, et al.
J Urol
. 2015 Aug;
194(6):1617-23.
PMID: 26272031
Purpose: We identified prognostic biomarkers in prostate cancer by a radiogenomics strategy that integrates gene expression using the cell cycle progression score and medical images. Materials And Methods: We obtained...